Ellington Management Group LLC purchased a new position in shares of TG Therapeutics Inc (NASDAQ:TGTX) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,700 shares of the biopharmaceutical company’s stock, valued at approximately $203,000.

A number of other large investors also recently modified their holdings of the stock. California State Teachers Retirement System grew its position in TG Therapeutics by 1.9% during the second quarter. California State Teachers Retirement System now owns 85,935 shares of the biopharmaceutical company’s stock worth $864,000 after buying an additional 1,600 shares in the last quarter. First Mercantile Trust Co. grew its position in TG Therapeutics by 28.6% during the fourth quarter. First Mercantile Trust Co. now owns 26,701 shares of the biopharmaceutical company’s stock worth $219,000 after buying an additional 5,938 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in TG Therapeutics by 26.2% during the second quarter. The Manufacturers Life Insurance Company now owns 36,754 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 7,630 shares in the last quarter. Allianz Asset Management GmbH grew its position in TG Therapeutics by 6.6% during the fourth quarter. Allianz Asset Management GmbH now owns 137,980 shares of the biopharmaceutical company’s stock worth $1,131,000 after buying an additional 8,602 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in TG Therapeutics by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 462,270 shares of the biopharmaceutical company’s stock worth $3,790,000 after buying an additional 8,699 shares in the last quarter. 50.63% of the stock is currently owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

A number of equities research analysts recently issued reports on TGTX shares. B. Riley started coverage on TG Therapeutics in a research report on Friday, December 1st. They set a “buy” rating and a $21.50 price target on the stock. HC Wainwright reissued a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a research report on Monday, December 11th. Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 11th. Finally, Zacks Investment Research downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $24.60.

In other TG Therapeutics news, CFO Sean A. Power sold 32,006 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $8.50, for a total value of $272,051.00. Following the sale, the chief financial officer now owns 517,464 shares of the company’s stock, valued at approximately $4,398,444. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 16.70% of the company’s stock.

Shares of TGTX stock opened at $16.00 on Wednesday. The firm has a market capitalization of $1,224.39, a price-to-earnings ratio of -8.38 and a beta of 1.40. TG Therapeutics Inc has a twelve month low of $7.25 and a twelve month high of $17.35.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.46). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 145.58% and a negative net margin of 77,945.40%. equities research analysts predict that TG Therapeutics Inc will post -1.68 earnings per share for the current year.

WARNING: “Ellington Management Group LLC Purchases New Stake in TG Therapeutics Inc (TGTX)” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/ellington-management-group-llc-purchases-new-stake-in-tg-therapeutics-inc-tgtx/1951924.html.

TG Therapeutics Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics Inc (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.